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ABSTRACT
As of 2019, marijuana legalization and decriminalization is sweeping the globe.
Patients are increasingly using cannabis-derived compounds including Δ9tetrahydrocannabinol (THC) and cannabidiol (CBD) for treatment of diseases as diverse
as epilepsy, Parkinson’s disease, and cancer. Furthermore, mothers are claiming that
CBD oil decreases uncomfortable pregnancy side effects. While the adverse effects of
chronic cannabinoid use and of cannabinoids on pregnancy have been previously
investigated, the exact function of the endocannabinoid system, and its primary receptors,
cannabinoid receptors 1 and 2, involved in producing these outcomes is still unclear. In
this study, two strains of zebrafish embryos, namely fli and cnr2-/- were exposed to
varying concentrations of CBD and THC for 96 hpf and their developmental and
behavioral outcomes were observed to further determine the role that CB2 plays in
embryonic development and organogenesis. Fli larvae had a higher percent incidence of
pericardial edema and yolk sac edema when exposed to 0.6 mg/L CBD, whereas CBD
treated cnr2-/- were not significantly different than untreated. Fli larvae also showed an
increased percent incidence of yolk sac edema at 2.5 mg/L THC and a percent incidence
not different from control, or 2.5 mg/L at 1.25 mg/L, whereas cnr2-/- only suffered from
yolk sac edema at 2.5 mg/L THC. Behavioral patterns were treatment-dependent, as both
THC and CBD showed increased activity at 0.65 mg/L and 0.075 mg/L, respectively.
These studies indicate that cannabinoid developmental toxicity depends both on the
particular cannabinoid and its interactions with the CB2 receptor. Additional studies are
needed to investigate the THC and CBD toxicities in the cnr1-/- to further understand the
mechanisms of cannabinoid toxicity.
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I. Introduction
1.0 Cannabis
Society views cannabis in several ways due to its medicinal and recreational usage.
Some see cannabis as a gateway drug, preceding the use of other illicit and licit
substances and the development of substance abuse and addiction (“Is marijuana a
gateway drug? National Institute on Drug Abuse (NIDA),” n.d.). Others see this drug for
its therapeutic use in treating diseases, such as cancer, glaucoma, nerve pain, seizure
disorders, Crohn’s Disease, and muscle spasms due to multiple sclerosis (Elikkottil et al.,
2009). Many expecting mothers view cannabis as a method of avoiding hyperemesis
gravidarum (morning sickness), and other pregnancy discomforts (Roberson et al., n.d.).
Regardless of how this plant is stigmatized, cannabis is a blanket term for three species of
hemp plants (Cannabis sativa, Cannabis indica, Cannabis ruderalis) (“Is marijuana a
gateway drug? National Institute on Drug Abuse (NIDA),” n.d.). The term marijuana
describes the dried components from the hemp plant, such as leaves, seeds, and stems,
that are often smoked or eaten (Campbell et al., 2017).
Marijuana is classified into two categories: recreational and medical (What is
marijuana?, 2018). Recreational marijuana use has been legalized in nine states- Oregon,
Washington, Colorado, Alaska, Nevada, Maine, Massachusetts, California, Vermont- and
the District of Columbia as of March 2019 (Martin, 2018). Pushes for recreational
marijuana usage legalization has increased, with 60% of the American population
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supporting the idea, as most Americans believe that marijuana is not harmful and has no
adverse effects (Martin, 2018). Medical marijuana is the use of physician-prescribed
marijuana. Medical marijuana itself has not been approved by the U.S. Food and Drug
Administration (FDA), but it is often confused for FDA-approved drugs that contain
cannabinoids. Both recreational and medical marijuana can have the same harmful effects
during pregnancy, such as small birth size, stillbirth, and birth deformations (Gunn et al.,
2016). Many medical marijuana patients in California and in other states with legalized
medical marijuana often feel stigmatized by others (Satterlund et al., 2015).
Regardless of stigma and side effects of cannabis, the cannabis industry is rapidly
growing. Canada was the second country to fully legalize cannabis in October of 2018.
Since then, there has been a mass movement in Canada of cannabis producers working
with scientists on gene mapping, metabolic engineering, optimal drying techniques, and
growing practices in an effort to corner the global cannabis market (Dolgin, 2018).
Globally, the cannabis market is forecast to surpass US$57 billion within the decade
(Dolgin, 2018). Federal and provincial Canadian governments, government backed
organizations such as Genome Canada, and private investors are giving millions of
dollars to cannabis research to aid in this effort. In 2017 alone, Canadian cannabis
companies brought in US$1.5 billion, greater than half of worldwide funding raised by
legal cannabis firms, and the Canadian cannabis industry was projected to and did triple
that number in 2018 (Dolgin, 2018). As countries across the world have seen the ongoing
success of the Canadian cannabis industry, there has been an international trend toward
less restrictive laws around cannabis, allowing for further investment in genetic research.
This plant genetic research has allowed for the isolation and study of the two medically
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useful cannabinoids from the cannabis plant: Δ9-tetrahydrocannabinol and cannabidiol
(Dolgin, 2018).

1.0.1. Δ9-Tetrahydrocannabinol
Of cannabis drug chemotypes, Δ9-tetrahydrocannabinol is the most common
phytocannabinoid. In its acid form, THC is produced in the cannabis plant via an allele
codominant with CBD. The primary difference between THC and CBD is that THC
produces psychoactive effects once burned (Russo, 2016). THC causes these effects
through weak partial agonist activity at cannabinoid receptors 1 and 2 (CB1, CB2), which
results in the common effects of ingesting cannabis, such as increased appetite, reduced
pain, and changes in emotional and cognitive processes (Russo, 2016). THC is also a
neuroprotective antioxidant, bronchodilator, antipruritic agent in cholestatic jaundice, and
is a better anti-inflammatory than both aspirin and hydrocortisone (Russo, 2016).
Dronabinol (marketed as Marinol) is a medication utilizing synthetic THC that is
prescribed to treat anorexia in AIDS patients and nausea and vomiting associated with
cancer chemotherapy.

1.0.2 Cannabidiol
Cannabidiol (CBD) is the main non-intoxicating phytocannabinoid produced by
the cannabis plant. CBD is currently being produced in marijuana legalized states without
any regulation, resulting in products that vary widely in purity (Thompson and Kearney,
2016). CBD has a low affinity for cannabinoid receptors but has CB1 and CB2
independent mechanisms. These mechanisms may account for CBD’s ability to act as a
negative allosteric modulator at CB1 receptor sites (Laprairie et al., 2015). Dispensaries
sell CBD products in states with legalized marijuana and no CBD-specific laws. Only
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physicians can provide CBD products in states that have not legalized marijuana due to
restrictions on CBD dispensing. CBD-enriched extracts have been tested and
administered primarily in relation to medicinal use to treat anxiety, inflammation,
sleeplessness, and seizure activity.
In animal models, CBD has proven to lack adverse psychoactive effects, abuse
liability and have a better defined anticonvulsant profile than THC (Rosenberg et al.,
2015). Due to these factors, physicians have increased the use of CBD-enriched extracts,
such as the FDA approved CBD medication Epidiolex, to treat seizure disorders
especially in children (Reddy and Golub, 2016; Thompson and Kearney, 2016). Data
regarding the use of CBD-enriched extracts in treatment show improvement in seizure
control, sleep, and behavior; this data has been difficult to interpret due to lack of control
in these observations (Consroe et al., 1982; Jones et al., 2010; Klein et al., 2017).
However, three therapy trials for a purified CBD product utilizing high-quality placebo
control were performed on patients with epilepsy syndromes (Devinsky et al., 2014).
These studies demonstrated CBD superior to placebo in improving seizure control in
patients with both Dravet syndrome and Lennox-Gastaut syndrome epilepsy. While these
results are the first indication that CBD is useful in treating seizures, the exact biological
mechanism of how CBD induces seizure control are unknown (Perucca, 2018).
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Table 1. Summary of THC and CBD chemical properties. All THC information was acquired
from pubchem.ncbi.nlm.nih.gov. All CBD information was acquired from drugbank.ca.

THC

CBD

C21H30O2
314.469 g·mol−1
10.6
6.97
2.8 mg/L

C21H30O2
314.469 g·mol−1
9.13
6.1
1.26 mg/L

Structure

Molecular formula
Molecular weight
pKa
log kow
Water solubility at 23 C

1.1 Endocannabinoid system
The endocannabinoid system is composed of cannabinoid receptors expressed
throughout the mammalian central and peripheral nervous system and endocannabinoids.
Endocannabinoids like anandamide are endogenous lipid-based retrograde
neurotransmitters that act as ligands for cannabinoid receptors (Di Marzo et al., 2007).
Endogenous cannabinoids are eicosanoids, compounds derived from polyunsaturated
fatty acids that play a vital role in cell signaling (“Eicosanoid" Definition of Eicosanoid
by Merriam-Webster,” n.d.). Phytocannabinoids, such as THC and CBD, share the
lipophilic nature of eicosanoids, giving them the capability to nonspecifically alter
membrane permeability and interact with specific receptor binding sites, specifically CB1
and CB2 (Di Marzo et al., 2007). Other receptors in the endocannabinoid system include
orphan G-protein coupled receptors, such as GPR18, GPR55, and GPR119, and TPRV
proteins (Irving et al., 2017). The endocannabinoid system as a whole is not fully
understood at this point and is an active area of ongoing research.
In terms of function, the endocannabinoid system is involved in several
physiological processes, such as inflammation, learning, memory, cardiovascular
function, pain, emotional regulation and stress, and the sleep/wake cycle (“KEGG
5

DRUG: Dronabinol,” n.d.). Through the CB1/CB2 independent or cooperative
interaction— based on a neuronal population’s role in regulating physiological
function— these receptors are involved in mood and cognition alterations and other
cannabinoid induced central nervous system effects (NCBI, 2018; Onaivi et al., 2015).
The role of other orphan GPCRs is still being studied.
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Phytocannabinoids
Δ9-Tetrahydrocannabinol

Cannabivarian

Cannabidioldimethylheptyl

Cannabidiol

Ajulemic acid

Endogenous cannabinoids
Anadamide

2-Arachidonyl glycerol

2-Arachidonyl glycerol
ether
O-Arachidonyl
ethanolamine
N- Arachidonyl dopamine

Figure 1: List of cannabinoids: Phytocannabinoids, Synthetic cannabinoids, and
Eicosanoids. All figures were acquired from pubchem.ncbi.nlm.nih.gov and drugbank.ca.
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1.1.1 CB1
Cannabinoid receptor type 1 is located throughout the central and peripheral nervous
system (Polston and Wallace, 2017). According to NCBI, the highest concentrations of
CB1 are in the brain, then fat cells, then the placenta (Jiang et al., 2007). CB1 is a member
of the guanine protein coupled receptor family and are coupled to pertussis toxin
sensitive G-protein. This coupling suppresses adenylate cyclase and cAMP formation
upon activation of the receptor, resulting in lesser signal amplification and reaction to
signals (Howlett et al., 2010). However, CB1 also activates G-protein coupled receptors
via activation of specific isoforms of adenylate cyclase (Elikkottil et al., 2009). CB1
stimulates cAMP by coupling to G-proteins when the dopamine receptor 2 is activated in
striatal neurons (Maneuf and Brotchie, 1997). This results in the activation of dopamine
receptors in the brain. Also, CB1 receptors are found in both the central and peripheral
nervous system, and are most abundant in the hippocampus and amygdala, which are the
areas of the brain responsible for short-term memory storage and emotional regulation
(Kaur et al., 2016). Considering this relationship between CB1 and dopamine receptors
and CB1 location, CB1 has been linked to diseases such as Parkinson’s disease,
schizophrenia, depression, drug addiction, eating disorders, and autism spectrum
disorders (Onaivi et al., 2015a; Politis et al., 2017).

1.1.2 CB2
Cannabinoid receptor 2 is also located throughout the peripheral and central nervous
systems, however it is primarily located on lymphoid tissue and in inflammatory cells
(monocytes, mast cells, B/T cells), as it is involved in immune function regulation (Kaur
et al., 2016). CB2 is found in peripheral tissues, such as the GI tract, cardiovascular
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system, liver, bone, adipose tissue, and reproductive system (Polston and Wallace, 2017;
Zou and Kumar, 2018). CB2 is also a member of the guanine protein coupled receptor
family and is coupled to pertussis toxin sensitive G-protein. This coupling suppresses
adenylate cyclase and cAMP formation upon activation of the receptor, resulting in lesser
signal amplification and reaction to signals (Howlett et al., 2010). Unlike CB1, CB2 only
has inhibitory effects as it blocks production of adenylate cyclase and cAMP. As
inflammatory cells are generated in bone marrow and CB2 has been found in bone, both
deletion and overexpression of CB2 has been linked to bone deformity and development
(Lerner et al., 2008). However, the exact function and mechanism of CB2 is not yet clear.

1.2 Past cannabinoid receptor studies yield inconclusive data
Literature has shown that the deletion of CB1 results in different intra-species
phenotypes (Lerner et al., 2008). For example, two opposing studies regarding bone
formation were performed on different strains of mice. In one strain, deletion of CB1
resulted in decreased rate of bone formation, increased osteoclast count, and a low bone
mass phenotype (Tamm et al., 2013). In another strain, deletion of CB1 resulted in a
higher bone mass phenotype and genetic protection from ovariectomy-induced bone loss
(Bab and Zimmer, 2008). Due to conflicting studies such as these, the exact function of
CB1 has not been elucidated.
There is even less known about the exact function of CB2 than that of CB1. While not
primarily located in the central nervous system, CB2 has neuronal and functional
expression in the brain, and therefore, a role in neuropsychiatric disorders (Onaivi et al.,
2015b). CB2 has also been linked to bone formation; the deletion of the cannabinoid
receptor 2 gene in mice caused increased bone turnover and subsequent low bone mass
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phenotype (Ofek et al., 2006). CB2 mRNA was also detected in osteoblasts, osteoclasts,
and osteocytes (Lerner et al., 2008).

1.3 Adverse outcomes of cannabinoid exposure
With cannabis on the forefront of medical advancement, it is important to know how
this drug affects people, especially children and the elderly. As cannabis is a promiscuous
drug and participates in nonspecific ligand binding, cannabis can affect individuals
differently based on genetics, environment, potency of the drug, and purity of compound
(Di Marzo et al., 2007; Martin, 2018). For example, one study reported no association
between cannabis exposure and fetal congenital malformations after analyzing data from
153 cannabis non-users and 4,892 cannabis users (Warshak et al., 2015). On the other
hand, another study found an association between higher rates of cannabis use and 19 of
54 selected malformations (Forrester and Merz, 2006). While an association was found,
the study did not consider confounding variables, other substances, or multiple
comparisons, as the study only performed bivariate comparisons. Two case studies also
found a relationship between cannabis use and fetal malformations, but, due to the nature
of a case study, these results cannot be applied to the greater population (Gunn et al.,
2016).
THC causes short and long term effects, which can vary depending on the person and
the potency (Martin, 2018). Short term effects of THC exposure in humans include
impaired ability to think and solve problems, coordination, judgment, memory, and mood
(Crean et al., 2011). The effects of chronic use include memory loss, trouble learning and
thinking, changes in brain structure, and trouble in the work place (Crean et al., 2011). In
terms of bodily health, THC ingestion by vaporization or dabbing, two means of
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smoking, can lead to issues in lung function, such as chronic cough and trouble breathing
(Russell et al., 2018). Over-exposure to THC can cause adverse effects including intense
nausea and vomiting, increased heart rate, which may increase one’s risk of heart attack,
and mental health disorders, such as depression, anxiety, schizophrenia, psychosis, and
neurodevelopment deficiencies in adolescents (Borgelt et al., 2013; Meier et al., 2012).
There is scant literature regarding the short and long term effects of CBD exposure.
The developmental effects of transplacental and post-natal exposure to THC has not
been well researched. Early research suggests that mothers who smoked marijuana during
pregnancy gave birth to children with emotional, attention, memory, and impulsive
behavioral issues (Huizink and Mulder, 2006). THC can also diffuse into breast milk, but
the effects on the brains of babies drinking contaminated breast milk are not clear
(National Academies of Sciences et al., 2017). Studies also show that marijuana use
during pregnancy can produce fetal adverse outcomes, such as low birth weights and
physical deformities (Shiono et al., 1995). However, the relationship between cannabis
use during pregnancy and other outcomes, such as still birth, developmental deformities,
etc., are still unclear (Gunn et al., 2016). Regarding behavioral effects of early age THC
exposure, mice exposed to cannabinoids at adolescence suffered from decreased
reactivity of the dopamine reward centers found in the brain; these findings suggest that
THC has adverse impacts on early age behavior (Fransquet et al., 2017).
The potential developmental effects of early age CBD exposure have not been
well studied either. In terms of physiology, organogenesis, development, and behavior,
there is little literature regarding the effects of CBD exposure.
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1.4 Zebrafish as a model organism
Zebrafish is the model organism for this study for several reasons. First of all,
zebrafish are very easy to keep and breed. Zebrafish are relatively small, as the adult
zebrafish usually does not grow more than 5-6 cm in body length. Zebrafish also
naturally live in large groups. Therefore, large quantities of zebrafish can be kept in a
fairly restricted space (Glass and Dahm, 2004). Secondly, zebrafish produce large
numbers of translucent embryos when spawned. The translucent nature of the embryos,
and even the larvae during their first few days of development, allow for scientists to
observe embryonic development in real time. These embryos also develop very rapidly.
At 24 hours post fertilization (hpf), all major zebrafish organs are recognizable but not
yet functioning. At 24-48 hpf, cell types differentiate, causing organs to gradually begin
working. At 49-72 hpf larvae hatch and begin swimming and hunting for food by 120
hpf. At 3-4 months post fertilization, zebrafish reach sexual maturity (Glass and Dahm,
2004). Large numbers of offspring production, embryo transparency, and rapid
embryonic development make the zebrafish the ideal model for observing how genes
regulate embryonic development and behavior (Glass and Dahm, 2004)
The zebrafish is also a particularly good model for human pharmaceutical testing.
According to Langheinrich (2003), zebrafish embryos elicit comparable responses to
mammalian embryos when exposed to cardiovascular, anti-cancer, and anti-angiogenic
drugs. Approximately 70% of zebrafish proteins correspond to human orthologs.
Langheinrich also found that humans and zebrafish showed a near 100% similarity in
genes encoding highly conserved functional domains, especially substrate-binding
regions for drug-binding targets (Langheinrich, 2003).
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Due to the homology in zebrafish and human drug-binding regions and other
functional regions, the similar effects of drugs on both zebrafish and mammalian
embryos, and the transparency of the embryos and larvae allowing for visualization of
drug effects, the zebrafish is the appropriate model to use when testing the effects of
CBD and THC on development and behavior. Specifically, CB1 and cnr1 and CB2 and
cnr2 are similar in function and binding specificity (Langheinrich, 2003). Past studies of
THC/CBD in zebrafish have shown that early age exposure results in physical deformity
and behavioral alterations (Carty et al., 2018).

1.5 Research goals
The goal of this study was to further our understanding of the function of CB2.
This was accomplished by exposing cnr2-/- and fli strains of zebrafish to both THC and
CBD. After the exposure, we tested larval behavior and scored each fish for physical
malformations. We ran statistical analyses for physical deformities and behavior, testing
for significance between treatments and strains. With this information, we tested our
hypothesis: CB2 is involved in the developmental and behavioral adverse outcomes
caused by cannabinoid exposure.
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II. Methods
2.0 Zebrafish breeding and egg collection
Tu (cnr1; zf679) and Tu (cnr2; zf680) zebrafish were kindly gifted from Dr.
Wolfram Goessling’s lab at Harvard University (2012). Adult zebrafish were placed in
breeding tanks containing water (pH 7.5-8.0, dissolved oxygen 7.2-7.8 mg/L,
conductivity 730-770 µS, temperature 27-29 oC) from Aquatic Habitats zebrafish flow
through system (Aquatic Habitats, Apopka, Florida). These breeding tanks are smaller
boxes that fit into the tanks with holes large enough for eggs and waste to fall through but
not large enough for the fish to get through. Water in the tank was approximately two
inches above the bottom of the breeding box. This water level is important to the level of
reproductive hormone present in the tank to encourage spawning (Graham et al., 2018).
Zebrafish were spawned in these conditions overnight. The next morning, fertilized eggs
were collected by tank, placed into petri dishes, and adult zebrafish were returned to their
tanks. Waste and unfertilized eggs were removed from the petri dishes, and the number
recorded for fecundity data. System water was removed and replaced with egg water with
salinity 60 ppm Instant Ocean (Instant Ocean, Cincinnati, Ohio) at pH 7.4-7.7. Dr.
Zacharias Pandelides kindly provided fli larval deformity and behavioral raw data for this
study.
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2.1 Exposure
The goal was to treat embryos at or near the start of the gastrula period at the 50%
epiboly stage (5.3 hpf; ~5 hpf). Starting at 5 hpf allows enough time to sort and stage the
embryos; it also allows for the development of CB1 and CB2 receptors from the four and
one cell stage, respectively, to the end of the blastula stage (Kimmel et al., 1995; Paria
and Dey, 2000). The germ ring stage is the beginning of the gastrula period. Embryos are
all staged to be within 30 minutes of each other to provide accuracy in this developmental
study, which subsequently ensures experimental reproducibility and the ability to add
new observations and details (Kimmel et al., 1995). We routinely staged zebrafish within
an hour of collection to confirm they were fertilized at the same time. Embryos were
then assessed an hour before exposure to ensure that the exposure would be starting at the
correct stage (50% epiboly).
Exposure groups were a solvent control (dimethyl sulfoxide, (DMSO, 0.05%)
CBD (0.075, 0.15, 0.3, 0.6, and 1.2 mg/L; 0.25, 0.5, 1, 2, and 4 µM), or (DMSO 0.1%)
THC (0.625, 1.25, 2.5, 3.0, and 3.75 mg/L; 2.1, 4, 8, 12, and 16 µM). DMSO is a polar
aprotic solvent that dissolves both polar and nonpolar compounds
(pubchem.ncbi.nlm.nih.gov). These concentrations of CBD and THC were based on
previously described experimental data (Carty et al., 2018). Staged embryos were then
randomly sorted into scintillation vials, n=5 vials per exposure group; 20 embryos per
vial (thinned to 10 at 24 hpf), containing egg water. This exposure was carried out double
blind. To start the exposure, at 5 hpf egg water was drained from each scintillation vial
and 12 mL of treated water (0.6 mL water per embryo) was added. Water was not
changed throughout the exposure. Vials were then covered with tinfoil and placed into an
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incubator at 28o C. Exposed embryos were screened every 24 hours to remove debris,
waste, mortality, and sloughed chorions. At 24 hpf, replicate vials were thinned to the
desired 10 embryos, which remained in the original dosing vials for the remainder of the
exposure time. The mentioned exposure protocol followed the approved OECD
guidelines and recommendations; however, eggs were not exposed at 1 hpf due to timing
inconvenience and the lack of cnr1 presence at this time point. The NIDA Drug Supply
Program provided THC and CBD for this study. Following exposure, water samples were
taken down and cleaned up for later quantification and Gas Chromatography/Mass
Spectroscopy testing. The GC/MS was out of order for the latter duration of this study.

2.2 Larval behavior
At 96 hpf, larvae were transferred from scintillation vials to a 96-well plate to
assess behavior. Zebrafish larval behavior was then monitored via a ViewPoint Zebrabox
(ViewPoint, Montreal, Canada) for 30 minutes. In the Zebrabox, larvae underwent
light:dark:light cycling (0-10 min, 100% light (8000 lux), 10-20 min, 0% light (0 lux),
20-30 min, 100% light). For each well, larval travel duration at a velocity greater than or
equal to 5 mm/sec was recorded. This data was then pooled per scintillation vial and
statistical analyses were performed using a One-way ANOVA test to analyze the dark
cycle data. Following the Zebrabox behavior assessment, zebrafish were screened for
touch response, where the larval tail was touched with a pipette tip. This mechanical
impact either elicited an avoidance swimming response (as to be expected) or did not
elicit a response at all. Those that did not elicit a touch response or displayed gross
physical deformities were removed from behavioral statistical analysis.
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2.3 Developmental deformity scoring
Following behavioral assessments, larvae were anesthetized in 300 mg/L tricaine
methanesulfonate (MS-222) and 600 mg/L sodium bicarbonate. They were immediately
placed on a microscope slide with a chamber containing 3% methyl cellulose, and photos
were captured with a MicroFire® camera (Optronics, Goleta, CA) attached to a Zeiss
Stemi 2000-C Stereo Microscope (Jena, Germany) using Picture Frame™ Application
2.3 software (Optronics, Goleta, CA). A lateral photo of each larval fish was taken and
subsequently scored for physical deformities (no swim bladder, yolk sac edema,
pericardial edema, body axis curvature, micropthalmia, tail) by two independent
observers blinded to the treatments. Following imaging, the fish were placed in vials of
RNAlater and stored at -80°C for future analysis.

2.4 Statistical analysis
Error was identified as standard error of the mean (SEM) for all data points. LC50
data was assessed using the USEPA’s TRAP LC50 calculations. Physical deformity data
comparison between both treatment and strain were assessed using a two-way ANOVA
followed by a Tukey’s post hoc test. Data for each deformity was also assessed using
one-way ANOVA followed by Tukey’s post-hoc test (p≤0.05; n=5).
Throughout a 30-minute period, we continuously collected movement data for
each larval zebrafish at a velocity of ≥ 5 mm/s for larval zebrafish locomotor behavior
statistical assessment. Every 2 minutes, the average for activity duration per fish was
recorded for each dark or light phase for statistical analysis (n=5). The dark behavioral
data was averaged for each fish, pooled by concentration iteration, and analyzed using a
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one-way ANOVA followed by a Dunnett’s post-hoc test (p ≤ 0.05). All statistical
analysis was conducted using Sigma Plot software.
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III. Results
3.0 Lethality of THC and CBD
After waterborne exposure to either CBD or THC, 96 hpf zebrafish larvae
exhibited treatment and strain dependent morphological and behavioral toxicities. The
CBD exposed fli LC50 of 0.72 ± 0.34 mg/L was 28% lower than the CBD exposed cnr2-/LC50 of 0.92 ± 0.14 mg/L. The THC exposed fli LC50 of 2.97 ± 0.31 mg/L was 13%
lower than THC exposed cnr2-/- LC50 of 3.35 ± 1 mg/L (Table 2). Comparing fli and
cnr2-/- when exposed to either CBD or THC, there was no significant difference in
average survival between fli and cnr2-/- at any concentration (Fig. 2). Therefore, survival
was not strain dependent, as THC and CBD affect fli and cnr2-/- similarly. However, the
LC50 estimations in this study were not ideal, as there were few if any mortality data
points during the linear phase of the LC50 graphs. Therefore, further studies should be
conducted using concentrations between 0.6 and 1.2 mg/L CBD and 2.5 and 3.75 mg/L
THC in order to calculate a more accurate LC50.
The CBD fli LC50 of 0.72 mg/L was 3.125 times lower than the THC fli LC50 of
2.97 mg/L. The CBD cnr2-/- LC50 of 0.92 mg/L was 2.64 times lower than the THC cnr2-/LC50 of 3.35 mg/L. fli and cnr2-/- exhibited higher sensitivity to CBD than THC, as the
average survival for both fli and cnr2-/- was significantly lower at lower CBD
concentrations than the average survival at THC concentrations (Fig. 3).
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Figure 2. Strain dependent LC50 comparison: Fli and cnr2-/- both show
increased mortality with increased CBD or THC concentration. The calculated
LC50 was not significantly different between the two strains (CI overlap).
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Figure 3. Treatment dependent LC50 comparison: Fli and cnr2-/- both show higher sensitivity to
CBD. However, these LC50 estimations were not ideal due to lack of mortality data points along
the linear phase of the LC50 graphs. Further study should be conducted using concentrations
between 0.6 and 1.2 mg/L CBD and 2.5 and 3.75 mg/L THC.
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Table 2. LC50 confidence interval data: Estimated LC50, upper confidence interval (UCL), and
lower confidence interval (LCL) for CBD cnr2-/-, THC cnr2-/-, CBD fli, and THC fli.

cnr2
fli

CBD
Guess
0.92
0.72

-/-

95% LCL
0.78
0.38

95% UCL
1.06
1.06

THC
Guess
3.35
2.9696

95% LCL
2.35
2.6596

95%UCL
4.35
3.2496

3.1 CBD
3.1.1 CBD morphology
The percent incidence of physical deformities in both fli and cnr2-/- fish were
significant when comparing both strain and treatment according to two-way ANOVA (p
≤ 0.05). Namely, yolk sac edema and pericardial edema showed significantly increased
percent incidence due to strain and treatment (p ≤ 0.05). Exposure to control, 0.075,
0.15, 0.3, and 0.6 mg/L CBD did not result in any significant incidence of micropthalmia
(eyes), axis, or malformed tail in fli and cnr2-/- fish (p > 0.05). The 1.2 mg/L treatment
was excluded from comparison because mortality was ~100 percent at this treatment for
both strains.
Control

Micropthalmia

PE minor

fli 0.6 mg/L

fli 0.1% DMSO

fli 0.6 mg/L CBD

fli 0.6 mg/L CBD

YSE

PE

PE intermediate

fli 0.6 mg/L CBD

fli 0.6 mg/L CBD

Axis
fli 1.25 mg/L THC

fli 0.6 mg/L CBD

PE major

Tail
fli 3.75 mg/L THC

fli 0.6 mg/L CBD
fli 0.6 mg/L CBD

Figure 4. Physical Deformities in Zebrafish: Imaging fish at 2X magnification, we were able to
capture photos for more accurate deformity scoring. Each of the fish above exhibit either yolk sac
edema (YSE), axis, micropthalmia, pericardial edema (PE), or tail malformations. These
malformations were scored compared to a healthy control fish void of malformations. Minor PE
is often overlooked; therefore, PE severity is also depicted in the figure.
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Yolk sac edema (YSE) incidence was statistically significant across treatment and
strain (Fig. 4). The fli exposed to 0.6 mg/L CBD had 62.5 ± 20.1 % YE which was
significantly higher than all treatments except 0.6 mg/L cnr2-/-. There was no significant
difference between any other treatments or the strains.
In fli larvae, pericardial edema (PE) incidence was significantly increased across
both treatment and strain (Fig. 5). In fli larvae at 0.6 mg/L, the incidence of PE was
30.0 ± 3.7%, which was significantly greater than PE incidence at all other fli exposure
treatments. There was a significant 27.8% percent increased incidence at 0.6 mg/L CBD
in fli compared to the cnr2-/- fish. There was less than a 5% incidence of PE at 0.6 mg/L
and no incidence of PE for the cnr2-/- fish at control, 0.075, 0.15, and 0.3 mg/L.

-/-
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Figure 5. Percent incidence of YSE between fli and cnr2-/- Using a one-way ANOVA, we
assessed the average percent incidence of YSE ± the standard error for each CBD treatment
(n=5). Percent incidence of YSE between fli and cnr2-/- larvae: fli 0.6 mg/L exposed larvae
showed significantly greater YSE percent incidence than other treatment groups.
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Figure 6. Percent incidence of PE between fli and cnr2-/-: Using a one-way ANOVA, we
assessed the average percent incidence of PE ± the standard error for each CBD treatment
(n=5). Percent incidence of PE between fli and cnr2-/- larvae: fli 0.6 mg/L exposed larvae
showed significantly greater PE percent incidence than other treatment groups.
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Table 3. Summary table of CBD malformations: Mean percent incidence and standard error
(mean ± SE) of each malformation found in both fli and cnr2-/- strain fish. An asterisk indicates
significant increase percent incidence of toxicity.

CBD Malformations (%)
Treatment
(mg/L)
0.05% DMSO

Strain

YSE

PE

Axis

Eyes

Tail

cnr2-/-

4.0 ± 4.0

2.0 ± 2.0

6.0 ± 2.4

4.0 ± 4.0

2.0 ± 2.0

-/-

0.075
0.15
0.3
0.6

cnr2

5.0 ± 2.0

0.0 ± 0.0

4.2 ± 2.6

0.0 ± 0.0

0.0 ± 0.0

-/-

cnr2
cnr2-/cnr2-/-

0.0 ± 0.0
3.5 ± 2.9
26.9 ± 2.8

0.0 ± 0.0
0.0 ± 0.0
2.8 ± 2.8

0.0 ± 0.0
8.4 ± 4.3
23.6 ± 9.7

0.0 ± 0.0
0.0 ± 0.0
5.6 ± 5.6

0.0 ± 0.0
0.0 ± 0.0
0.0 ± 0.0

1.2
0.05% DMSO

cnr2-/fli

n/a
24.0 ± 7.4

n/a
0.0 ± 0.0

n/a
2.0 ± 2.0

n/a
0.0 ± 0.0

n/a
2.2 ± 2.2

0.075
0.15
0.3
0.6

fli

8.0 ± 3.7

2.0 ± 2.0

2.0 ± 2.0

0.0 ± 0.0

0.0 ± 0.0

fli
fli
fli

3.3 ± 2.6
19.2 ± 4.1
62.5 ± 20.1*

0.0 ± 0.0
2.0 ± 2.0
30.0 ± 3.7*

3.3 ± 2.6
4.2 ± 2.6
12.5 ± 6.7

0.0 ± 0.0
0.0 ± 0.0
5.0 ± 4.5

0.0 ± 0.0
4.2 ± 2.6
0.0 ± 0.0

1.2

fli

n/a

n/a

n/a

n/a

n/a

3.1.2 Behavior of cnr2-/- exposed to CBD
Zebrafish larval behavior was assessed via speed and duration of movement
during light and dark conditions. Wildtype zebrafish larvae tend to exhibit
hypolocomotor activity during light periods and hyperlocomotor activity during dark
periods (Kirla et al., 2016). CBD exposed cnr2-/- light/dark larval behavioral assessment
is in accordance with what was expected (Fig. 6). Therefore, movement in the dark at a
velocity ≥5 mm/s- was the focus in this study.
cnr2-/- larvae exposed to 0.075 mg/L CBD exhibited a significant 79.72% increase
in movement duration (seconds of duration ≥5 mm/s) during dark periods compared to
control larvae. CBD 0.15, 0.3, and 0.6 mg/L treatments did not show significant
differences in duration of movement during dark periods from control.
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Figure 7. CBD light/dark behavioral patterns in cnr2-/-. In the graph above, each dot represents the
average activity over a two minute time interval ± the standard error for each treatment (n=300).
cnr2-/- exhibited hypolocomotor activity during periods of light exposure, as seen in the first and
last ten minute intervals. The hyperlocomotor activity period occurs during the dark period, as
seen by the gradual increase, spike, and decrease in activity from 10-20 minutes. To decrease
standard error, the sample size should be increased and each fish should pass the swim-up test to
be included in analysis.
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Figure 8. CBD cnr2-/- average dark period locomotion: Using a one-way ANOVA, the average
duration of activity (velocity ≥ 5 mm/s) was assessed for each fish (n=300) during dark exposure
in larval zebrafish. CBD exposed larvae exhibited non-monotonic dose-dependent behavioral
patterns. Compared to control, the 0.075 mg/L treatment group showed the largest activity
duration, 0.15, 0.3, and 0.6 mg/L exposed larvae had activities that were not different than control
fish.
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3.2 THC
3.2.1 THC morphology
The percent incidence of physical deformity in both fli and cnr2-/- fish were
treatment dependent according to two-way ANOVA statistical tests. Yolk sac edema,
micropthalmia, pericardial edema, axis curvature, and malformed tail were not
significantly percent different between strain or treatment at control, 0.65, 1.25, and 2.5
mg/L treatments, and 3.00 mg/L and 3.75 mg/L were excluded from comparison due to
either ~100 percent mortality or lack of replication in fli.
Previous studies showed that embryos exposed to THC suffered from yolk sac
edema. Yolk sac edema was not statistically different across strain (Fig. 7). fli exposed to
2.5 mg/L exhibited a percent incidence of 56.7 ± 14.8%, which was significantly greater
than all other treatments except cnr2-/-1.25 and 2.5 mg/L and control larvae. At 1.25
mg/L, cnr2-/- had statistically more yolk sac edema than fli.

2-/-
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Figure 9. Comparison of YSE percent incidence between fli and cnr2-/-: Using a one-way
ANOVA, the average percent incidence of YSE ± the standard error for each THC treatment
(n=3) was assessed. Percent incidence of YSE was significantly greater in fli and cnr2-/- in 2.5
mg/L exposed larvae, 1.25 mg/L exposed larvae, and control larvae. A high percentage of control
larvae showed yolk sac edema. Further study with a higher sample group is needed to explain this
phenomenon.
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Table 4. Summary table of THC malformations: Mean percent incidence and standard error
(mean ± SE) of each malformation found in both fli and cnr2-/- strain fish. An asterisk indicates
significant increase percent incidence of toxicity.

THC Malformations (%)
Treatment
(mg/L)

Strain

YSE

PE

Axis

Eyes

Tail

0.1%
DMSO
0.65

cnr2-/-

6.7 ± 11.56

0.0 ± 0.0

0.0 ± 0.0

0.0 ± 0.0

6.67 ± 11.56

cnr2-/-

0.0 ± 0.0

0.0 ± 0.0

3.3 ± 5.8

0.0 ± 0.0

3.3 ± 5.8

1.25

cnr2

-/-

31.25 ± 8.8

12.5 ± 0.0

25 ± 17.7

0.0 ± 0.0

12.5 ± 17.7

2.5

cnr2-/-

55.5 ± 9.6*

53.8 ± 29.6

55.8 ± 38.4

0.0 ± 0.0

12.5 ± 17.7

0.1%
DMSO
0.65

fli

19.0 ± 9.8

12.9 ± 1.1

53.3 ± 9.9

0.0 ± 0.0

4.8 ± 3.7

fli

7.0 ± 2.7

0.0 ± 0.0

10.7 ± 5.0

0.0 ± 0.0

0.0 ± 0.0

1.25

fli

8.7 ± 4.1

19.3 ± 9.1

17.1 ± 4.7

4.2 ± 2.6

6.2 ± 4.1

2.5

fli

56.7 ± 14.8

46.7 ± 15.5

31.3 ± 14.2

0.0 ± 0.0

9.3 ± 6.1

3.2.2 Behavior of cnr2-/- exposed to THC
THC cnr2-/- light/dark larval behavioral assessment was only in accordance with
wildtype zebrafish behavior at the lowest sub-lethal THC treatment (Fig. 10) (Kirla et al.,
2016).
Duration of movement at velocity ≥5 mm/s during the dark period of behavioral
analysis was also calculated after THC exposure (Fig. 11). Larvae exposed to 0.65 mg/L
THC showed a significant 83.93% increase in movement duration (seconds of duration
≥5 mm/s) during dark periods compared to control. THC 1.25, 2.5, and 3.75 mg/L
treatments did not show significant differences in duration of movement during dark
periods from control.

31

Figure 10. THC light/dark behavioral patterns in cnr2-/-. In the graph above, each dot represents
the average activity over a two minute time interval ± the standard error for each treatment
(n=180). cnr2-/- exhibit a reversal of the typical behavioral pattern: hyperlocomotor activity
during light periods and hyolocomotor activity during the dark period. The only concentration
that follows the typical behavioral pattern is the lowest THC concentration. Our control only
shows a slight and gradual increase in activity during the dark period and a spike in activity
during the last light period. To decrease standard error, the sample size should be increased and
each fish should pass the swim-up test to be included in analysis.
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Figure 11. THC cnr2-/- average dark period locomotion: Using a one-way ANOVA, the average
duration of activity (velocity ≥ 5 mm/s) during dark exposure in larval zebrafish dose-dependent
(n=180) was assessed. THC exposed specimen exhibit non-monotonic behavioral patterns.
Compared to control, the 0.65 mg/L treatment group showed the largest activity duration, and
1.25, 2.5, and 3.75 mg/L larvae were not statistically different than control.
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IV. Discussion
4.0 Lethality of THC and CBD
Our tested LC50 values for fli and cnr2-/- CBD and THC exposures confirm
previous LC50 data. THC LC50 values of cnr2-/- 3.35 mg/L and fli 2.97 mg/L confirmed
previous THC LC50 data (3.37 mg/L, 3.65 mg/L) (Akhtar et al., 2013; Carty et al., 2018).
CBD LC50 values of cnr2-/- 0.92 mg/L and fli 0.72 mg/L confirm previous CBD LC50
values (0.53 mg/L) (Carty et al., 2018). We expected CBD LC50 values to be lower than
than THC LC50 values, it was previously published that wildtype zebrafish exposure to
THC and CBD produced a CBD LC50 ~7 times lower than THC LC50 (Carty et al., 2018).
As Carty (2018) explained, lower CBD LC50 values cannot be attributed to increased
potency but to more efficient bioconcentration of CBD in larvae tissues. The slight
differences between our THC and CBD LC50 values and Carty (2018) LC50 values can be
attributed to the time of exposure. In Carty (2018), embryos were exposed at the
beginning of the blastula stage, and here embryos were not exposeduntil the end of the
blastula stage at 50% epiboly. According to previous studies, earlier life stage exposure
elicits increased frequency of dysmorphologies, leading to higher rates of mortality
(Bloch et al., 1986; Harbison et al., 1977; Outcomes et al., 2003).

4.1 CBD and THC morphology
CBD and THC exposure produced similar concentration-dependent toxicities,
namely yolk sac edema and pericardial edema. It was expected that that CBD and THC
would produce similar malformational outcomes in fli zebrafish development because of
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previous work in our laboratory (Carty et al., 2018). However, Carty (2018) noted several
morphologic outcomes in compound exposed fli larvae that we did not observe with
statistical significance: missing pectoral fins, swim bladder distention, axis,
micropthalmia, snout, jaw, and tail deformity. Like out study, Carty (2018) also noted
significant percent incidence in yolk sac edema and pericardial edema but at lower
concentrations than those at which we recorded. There are two reasons that can account
for these differences. First, Carty (2018) exposed embryos at an earlier life stage,
increasing the frequency of physical malformations (Bloch et al., 1986; Harbison et al.,
1977). Second, our experiment was double-blind, whereas Carty’s (2018) was not. A
double-blind experiment can produce more accurate data, because a double-blind
experiment reduces hypothesis bias in scoring malformations. Because of these
differences, we only saw significant increase in yolk sac edema and pericardial edema at
fli CBD 0.6 mg/L and yolk sac edema at fli and cnr2-/- THC 2.5 mg/L.

4.1.1 CB2 and cardiac function
CB1 and CB2 receptors have been located in the hearts of several mammalian
species: rat (Bouchard et al., 2003; Lépicier et al., 2003), mouse (Duerr et al., 2014),
guinea pig (Currie et al., 2008), and human (Weis et al., 2010). These receptors have also
been located on the hearts of zebrafish (Krug et al., 2015). These receptors are involved
in acute cardiovascular conditions, namely septic, hemorrhagic, and cardiogenic shock,
along with chronic diseases, such as heart failure, cardiomyopathy, and coronary heart
disease (Kaschina, 2016). By acting on these receptors, cannabinoids stimulate cardiac
function (Matsuda et al., 1990; Munro et al., 1993). In the cardiac system, CB2 acts as an
agent of cardiovascular protection against acute cardiovascular conditions, contributing
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anti-inflammatory, anti-atherogenic, and anti-oxidative abilities (Mukhopadhyay et al.,
2010; Steffens et al., 2005). Several studies have reported marked upregulation of CB2
following cardiac injury, such as myocardial infarction in rats (Wagner et al., 2001) and
ischemia/reperfusion in mice (Duerr et al., 2014). CBD has a low affinity for CB2, but at
increasing concentrations, CB2 becomes saturated with CBD (Kendall and Alexander,
2017). Our data shows that sub-lethal dose CBD exposure to fli strain zebrafish at early
life stages results in a dose dependent significant increase in percent incidence of
pericardial edema. In cnr2-/- fish exposed to the same concentrations of CBD, this adverse
outcome was not observed. Therefore, we concluded that CBD binding to CB2 could be
contributing to the cardiac toxicity seen in wildtype fish. CB2 receptor may interact in a
way to either allosterically alter the shape of the primary binding site, competitively
inhibit binding of other substrates, or act on the receptor in another form. Exposure to
THC did not have these effects most likely due to the fact that THC acts on CB2 in a
different fashion.

4.1.2 CB2 and hematopoiesis
The first site of hematopoiesis in zebrafish occurs in the intermediate cell mass,
which later develops in to the yolk sac and is comparable to the mouse amniotic sac
(Kulkeaw and Sugiyama, 2012). CB2 is primarily located on cells of hematopoietic origin
across species, and therefore is most likely found in the zebrafish yolk sac (Basu and
Dittel, 2011). When endogenous cannabinoids bind to CB1 and CB2 receptors in
hematopoietic cells, these cannabinoids act as growth stimulators for hematopoietic cells
and inhibitors of lymphocyte proliferation and tumor necrosis factorK production
(Derocq et al., 1998). Phytocannabinoid binding to CB1 and CB2 should produce similar
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effects. In our study, fli larvae suffered from yolk sac edema following exposure to CBD.
Both fli and cnr2-/- suffered from yolk sac edema following THC exposure. CBD binding
to CB2, may have caused uncontrolled growth of hematopoietic cells within the yolk sac.
This growth and proliferation resulted in yolk sac edema. In cnr2-/- larvae, only those
exposed to the highest sub-lethal concentrations of THC yielded percent incidence
similar to fli larvae at those concentrations. cnr2-/- at 1.25 mg/L THC showed
significantly higher percent incidence of yolk sac edema than fli. Control larvae also
showed a significant increase in yolk sac edema; further study with a higher sample size
should be conducted to investigate this finding. These results may be due to the fact that
THC interacts with CB2 differently than CBD.

4.2 Light/dark behavioral assessment
According to Kirla (2016), zebrafish tend to elicit hypolocomotor activity under
light conditions and hyperlocomotor activity under dark conditions. Our assessment of
CBD light/dark behavior corresponds to this finding. During the first and last ten minutes
of larval behavioral assessment, little to no movement greater than or equal to 5 mm/s
was recorded; these time periods correspond to the light periods of testing. There was a
dramatic spike in activity during the intermediate ten minute assessment interval, which
corresponded to the dark period. Our assessment of THC light/dark behavior did not
follow this model. In all treatments aside from 0.65 mg/L, there was no distinction in
activity levels between the light and dark phases. This trend indicates that higher THC
concentrations induce stress and anxiogenic-like behavior (Ellis et al., 2012). It also
suggests that a neurotoxic event induced by higher THC concentrations may be inducing
molecular signaling and altering behavior (Kim et al., 2013). Carty (2018) observed
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similar activity at higher exposure concentrations of both CBD and THC. We did not
observe these effects in higher concentrations of CBD, and this finding can be attributed
to later life stage exposure.

4.2.1 Dark phase behavioral assessment
According to several studies, both THC and CBD act as stimulants at low
concentrations (Achenbach et al., 2018; Akhtar et al., 2013). In Achenbach (2018),
average larval distance traveled was significantly higher at lower concentrations as
opposed to higher concentrations. Our data confirms these previous studies, as we found
that cnr2-/- larvae exposed to 0.075 mg/L CBD had a significantly greater duration of
activity during the dark period than larvae exposed to any other treatment. In Akhtar
(2013) and Carty (2018), larval behavior of THC exposed larvae were greater at lower
concentrations than higher concentrations.
We found that cnr2-/- larvae exposed to 0.65 mg/L THC had a significantly
greater duration of activity during the dark period than larvae exposed to any other
treatment. THC and CBD stimulate neuronal signaling pathways at low concentrations
and have either a normalizing or depressing effect at higher concentrations.

4.3 Conclusion
Our investigation into the effects of CBD and THC on specific receptors in the
endocannabinoid system is highly relevant in today’s world of ever expanding cannabis
research. Toxicology, epilepsy, and cancer research fields, to name a few, are beginning
to utilize cannabinoid enriched drugs in treatment. Additionally, pregnant women are
self-medicating with CBD. Therefore, it is important to know exactly how THC and CBD
interact with our bodies and may interfere with early development. In order to understand
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these potential adverse outcomes, it is important to understand the molecular mechanisms
by which these compounds primarily interact, including the endocannabinoid system and
its receptors, CB1 and CB2.
The endocannabinoid system is still very much a mystery, and even less research
has been conducted to understand the role of CB2. Through this study, I believe that we
have added a piece to the endocannabinoid puzzle by unveiling a few of CB2’s functions
in the presence of CBD and THC. In regards to organogenesis, CBD negatively affected
both cardiac and hematopoietic development via interactions with CB2. THC does not
appear to directly interact with CB2 to affect hematopoietic development. From our
studies, CB2 does not appear to play a major role in larval behavior, as behavioral
patterns for cnr2-/- exposed to either THC or CBD followed predicted, non-monotonic
behavioral patterns of wildtype fish exposed the same compounds. By understanding the
role of CB2, we can further understand the development of toxicities that THC and CBD
can cause and minimize the adverse outcomes mediated by developmental cannabinoid
exposure in the future.
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